SCHEMBL20963871

SCHEMBL20963871

COC(=O)c1cc(OC)cc(/C(N)=N/O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.48
▸ MAPT P10636 2/20 0.48
▸ POLB P06746 3/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ USP2 O75604 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ XDH P47989 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29278609 1.00 KDM4E (0.48) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL30614536 1.00 KDM4E (0.48) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL14738759 0.85 RXRA (0.45) KDM4EMAPTNPC1RAB9ACA1
SCHEMBL6976229 0.85 RXRA (0.45) KDM4EMAPTNPC1RAB9ACA1
SCHEMBL30497213 0.85 KDM4E (0.47) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL25301773 0.85 KDM4E (0.47) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL14738760 0.85 RXRA (0.45) KDM4EMAPTNPC1RAB9ACA1
SCHEMBL20963587 0.84 POLB (0.42) KDM4EMAPTPOLBCA1CA2
SCHEMBL2698400 0.84 GAA (0.50) KDM4EMAPTNPC1RAB9AATM
SCHEMBL2698398 0.84 GAA (0.50) KDM4EMAPTNPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 — — CN disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 — — EP disclosed
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-04 — — US disclosed
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS NR1H4, FXR1, NR1H2 KDM4E 3658/4885MAPT 573/4885POLB 4627/4885
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators NR1H4, FXR1, NR1H2 KDM4E 3658/4885MAPT 573/4885POLB 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback